lonelywarrior
Nov 17, 3:43 PM
$URGN This is the moment when
$CGON is downgraded though price target increased and the realization comes that
$URGN is in much stronger position business-wise with FDA-approved products generating revenue while
$CGON results are already priced-in and are unlikely to materialize as the actual FDA approval until 2028.
1 replies